

CD19 antibodies

Analyte specific reagents (ASR)

Analytical and performance characteristics were not established



Miltenyi Biotec B.V. & Co. KG

Friedrich-Ebert-Str. 68
51429 Bergisch Gladbach
Germany
☎ +49 2204 8306-8484
🌐 www.miltenyibiotec.com

1. General information

Intended use

REA675 reacts with human CD19. The fluorescently labeled CD19 antigen can be detected by flow cytometry.


Reagents and contents

Monoclonal CD19 antibody conjugates

Product	Volume	REF
CD19-PE	1 mL	170-081-066
CD19-APC	1 mL	170-081-067
CD19-PE-Vio770	1 mL	170-081-076

2. Technical data and background information

Antigen	CD19
Clone	REA675
Isotype	Recombinant human IgG1, κ light chain
Alternative names of antigen	B4, Leu-12
Purification	Affinity chromatography
Product formulation	Antibodies are supplied in buffer containing stabilizer and 0.05% sodium azide.



Store at +2 °C to +8 °C (+36 °F to +46 °F).



Store protected from light.



The use-by date is indicated on the vial label.



For in-use stability at +2 °C to +8 °C (+36 °F to +46 °F) storage temperature refer to the use-by date indicated on the vial label. Do not use the reagent after the use-by date.

Expression pattern

REA675 recognizes the human CD19 antigen, a type I transmembrane glycoprotein of 95 kDa that belongs to the immunoglobulin superfamily. CD19 is expressed on B cells throughout most stages of B cell differentiation, though its expression is down-regulated during their terminal differentiation to plasma cells. Expression of CD19 is also found in the majority of B cell-derived malignancies. CD19 is further present on follicular dendritic cells. On B cells, CD19 associates with CD21, CD81, and CD225 (Leu-13) forming a signal transduction complex. Additional information: Clone REA675 displays negligible binding to Fc receptors.

3. Warnings and precautions

- ▲ Interpretation of results is under the full responsibility of the user.
- ▲ For all handling, consideration of good laboratory practice (GLP) regulations is recommended.
- ▲ Use of the reagents is restricted to trained and qualified personnel only.

- ▲ All biological specimens and all materials that come into contact with blood and blood products must be treated as infectious material. Regulations for the treatment and disposal of infectious material must be followed.
- ▲ Reagents contain sodium azide (NaN₃), a chemical highly toxic in pure form. However, at product concentrations, it is not classified as hazardous. Sodium azide may react with lead and copper plumbing to form highly explosive buildups of metal azides. Upon disposal, flush with large volumes of water to prevent metal azide build-up in plumbing. Safety guidelines must be observed.
- ▲ For material required but not provided the manufacturers recommendations and safety regulations must be followed.
- ▲ Reagents should not be used if signs of leakage are observed. Use undamaged and sealed vials only.

4. Application

Reagents can be used for immunophenotyping by flow cytometry and other research applications.

5. General Use considerations

Principle of method:

The antibody reagent provided enables the identification of a specific target cell type by flow cytometry. This technique is based on fluorochrome conjugated antibodies binding to specific antigens expressed by the target cells. Incubating a sample of interest, e.g., peripheral blood mononuclear cells (PBMC), with the provided antibody reagent leads to fluorescent staining of the cell type expressing the specific target antigen. Analysis of the sample is performed in a flow cytometer at a single-cell level. The analysis is based on the detection of characteristic light emission patterns emitted by the fluorescently labeled antibody upon excitation with laser light. The collected data can be processed and analyzed using flow cytometry software.

Important notes:

Exposure of reagents to temperatures below +2 °C (+36 °F) and above +8 °C (+46 °F) and to light should be minimized during handling.

Sample requirements

- Reagents can be used for determination of antigen-positive cells in whole blood samples by flow cytometry.
- Each cell source can have different storage conditions and limitations that should be considered prior to collection and analysis. For collection of patient samples national legislation must be followed.
- Whole blood samples should be stained within 24 hours.
- Viability of the cells should be assessed and use of samples with at least 80% viable cells is suggested in order to minimize risk of erroneous results.

Quality control:

It is recommended to run regularly a control sample from a normal adult specimen or commercially available whole blood control as a quality control of the system.

6. Analytical specificity

Analytical specificity was evaluated by comparing REA675 to a relevant reference clone of the same specificity. Reactivity towards the same antigen was inferred from the antibody blocking capacity or the staining diagonal observed during co-incubation of REA675 with the reference clone. Measurements were performed using different donor samples. All measurements were within the acceptance criterion.

7. Excitation and emission data of fluorochrome conjugates

Fluorochrome	Excitation laser (nm)	Excitation maximum (nm)	Emission maximum (nm)
VioBlue®	405	400	452
VioGreen™	405	388	520
VioBright™ FITC	488	496	522
FITC	488	495	520
PE	488 or 561	565	578
PE-Vio®615	488 or 561	565	619
PerCP	488	482	675
PerCP-Vio®700	488	482	676
PE-Vio®770	488 or 561	565	775
APC	561 or 635	652	660
APC-Vio®770	561 or 635	652	775

8. Limitations

Combinations of recombinant human IgG, κ light chain antibodies with anti-human IgG1 or anti-human Ig κ light chain reagents can generate misleading results.











Use of monoclonal antibodies in patient treatment can interfere with recognition of target antigens by this reagent. This should be considered when analyzing samples from patients treated in this fashion. Miltenyi Biotec has not characterized the effect of the presence of therapeutic antibodies on the performance of this reagent.

Reagent data was collected typically with EDTA-treated blood. Reagent performance can be affected by the use of other anticoagulants.

9. References

1. Nadler, L.M. *et al.* (1983) B4, a human B lymphocyte-associated antigen expressed on normal, mitogen-activated, and malignant B lymphocytes. *J. Immunol.* 131(1): 244-250.
2. Fujimoto, M. *et al.* (2000) CD19 regulates intrinsic B lymphocyte Signal transduction and activation through a novel mechanism of processive amplification. *Immunol. Res.* 22(2-3): 281-298.
3. Poe, J. C. *et al.* (2001) CD19, CD21, and CD22: multifaceted response regulators of B lymphocyte Signal transduction. *Int. Rev. Immunol.* 20(6): 739-762.
4. Tedder, T. F. *et al.* (2002) CD19-CD21 complex regulates an intrinsic Src family kinase amplification loop that links innate immunity with B-lymphocyte intracellular calcium responses. *Biochem. Soc. Trans.* 30(4): 807-811.

10. Glossary of symbols

	Manufacturer		Use-by date
	Order number		In-use stability
	Batch code		Temperature limit
	Consult instruction for use		Protect from sunlight
	Phone		Website

MACS, the Miltenyi Biotec logo, Vio, VioBlue, VioGreen and VioBright are registered trademarks or trademarks of Miltenyi Biotec B.V. & Co. KG and/or its affiliates in various countries worldwide.

Copyright © 2020 Miltenyi Biotec and/or its affiliates. All rights reserved.